Two medicines, side by side
Doxycycline vs omadacycline
Doxycycline is labeled for urinary tract infections, bacterial infections and acne; omadacycline has no indication this site maps. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of doxycycline since 1967 and of omadacycline since 2018. In FDA's classes, doxycycline is a tetracycline-class drug and omadacycline a tetracycline-class antibacterial.
Check it at the source: the doxycycline FDA label on DailyMed (effective July 25, 2025); the omadacycline FDA label on DailyMed (effective May 27, 2026).
Highlights of the doxycycline record
Doxycycline (Vibramycin) · label of July 25, 2025
Used for
From the label: indicationsTo reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. […]
On the market
- Earliest approval on file
- December 5, 1967
- Generic labelers
- 83 labelers
- Pharmacy cost
- $0.118 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 19
Highlights of the omadacycline record
Omadacycline (Nuzyra) · label of May 27, 2026
Used for
From the label: indicationsNUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. […]
On the market
- Earliest approval on file
- October 2, 2018
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Doxycycline label of July 25, 2025, Omadacycline label of May 27, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do doxycycline and omadacycline differ on the record?
In FDA's classes, doxycycline is a tetracycline-class drug and omadacycline a tetracycline-class antibacterial.
Generics: doxycycline since 1973; omadacycline none approved (Drugs@FDA).
| Doxycycline | Omadacycline | |
|---|---|---|
| Labeled for | Urinary tract infections, Bacterial infections, Acne | n/a |
| Pharmacologic class | Tetracycline-class Drug | Tetracycline-class Antibacterial |
| How it works (label) | n/a | NUZYRA is an antibacterial drug [see Microbiology (12.4) ]. |
| Half-life (label) | 1.62 0.95 0.37 0.15 (μg/mL) Average Observed Values Maximum Concentration 3.61 μg/mL (± 0.9 sd) Time of Maximum Concentration 2.60 hr (± 1.10 sd) Elimination Rate Constant 0.049 per hr (± 0.030 sd) Half-Life 16.33 hr (± … | n/a |
| Earliest approval on file (Drugs@FDA) | December 5, 1967 | October 2, 2018 |
| First generic approved | June 18, 1973 | none |
| Generic labelers (NDC) | 83 labelers | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.118 per tablet (Doxycycline hyclate 100 mg tablet) | n/a |
| 12-month price change | -2% | n/a |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 19 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 69,571 | 1,642 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to doxycycline
- every medicine labeled for the same conditions